Free Newsletter
AstraZeneca floats $6.9 billion in bonds
AstraZeneca announced it has issued $6.9 billion in bonds on the U.S. market, planning to use the proceeds to retire a chunk of the short-term debt it took on for the $15 billion MedImmune buyout. Its interest rates range from 6.45 percent on 30-year fixed-rate notes to 5.4 percent on 5-year fixed notes.
With a total of $13 billion in commercial paper, the company will still have several billions to convert to long-term debt. Today, the company named three banking advisors--Citigroup, Deutsche Bank, and HSBC--to explore an additional bond issue in Europe.
- read the releaseÂ
- see the report from CNBC
Related Articles:
AstraZeneca snares MedImmune in $15.6B buyout. Report
MedImmune CEO talks about AZ buyout. Report
AstraZeneca cuts 7,600 jobs. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: